Federal Register / Vol. 75, No. 64 / Monday, April 5, 2010 / Rules and Regulations 17047 

§ 27.1457(a)(6); or § 29.457(a)(6) of this 

chapter, as applicable. 

(h) All airplanes or rotorcraft required 

by this part to have a cockpit voice 

recorder and a flight data recorder, that 

install datalink communication 

equipment on or after December 6, 2010, 

must record all datalink messages as 

required by the certification rule 

applicable to the aircraft. 

■ 19. Amend appendix C to part 135 by 

revising footnote 4 to read as set forth 

below. 

Appendix C to Part 135—Helicopter 

Flight Recorder Specifications 

* * * * * 

4 For all aircraft manufactured on or after 

December 6, 2010, the sampling interval per 

second is 4. 

■ 20. Amend appendix E to part 135 by 

revising footnote 3 to read as set forth 

below. 

Appendix E to Part 135—Helicopter 

Flight Recorder Specifications 

* * * * * 

3 For all aircraft manufactured on or after 

December 6, 2010, the sampling interval per 

second is 4. 

■ 21. Amend appendix F to part 135 by 

revising footnote 18 to read as set forth 

below. 

Appendix F to Part 135—Airplane 

Flight Recorder Specifications 

* * * * * 

18 For all aircraft manufactured on or after 

December 6, 2010, the seconds per sampling 

interval is 0.125. Each input must be 

recorded at this rate. Alternately sampling 

inputs (interleaving) to meet this sampling 

interval is prohibited. 

Issued in Washington, DC, on March 30, 

2010. 

J. Randolph Babbitt, 

Administrator. 

[FR Doc. 2010–7660 Filed 4–2–10; 8:45 am] 

BILLING CODE 4910–13–P 

DEPARTMENT OF TRANSPORTATION 

Federal Aviation Administration 

14 CFR Part 67 

[Docket No. FAA–2009–0773 

Special Issuance of Airman Medical 

Certificates to Applicants Being 

Treated With Certain Antidepressant 

Medications 

AGENCY: Federal Aviation 

Administration (FAA), DOT. 

ACTION: Policy statement; request for 

comment. 

SUMMARY: This policy statement is 

intended to serve as notice that the 

Federal Aviation Administration (FAA) 

will consider for a special-issuance 

medical certificate applicants for first-, 

second-, and third-class airman medical 

certification who are being treated for 

depression with one of four 

antidepressant medications. The FAA 

will evaluate affected applicants on a 

case-by-case basis and will issue 

certificates based on a medical finding 

that an individual’s use of such 

medication will not endanger public 

safety. 

DATES: This policy goes into effect April 

5, 2010. Comments must be submitted 

on or before May 5, 2010. 

ADDRESSES: You may send comments 

identified by Docket Number FAA– 

2009–0773 using any of the following 

methods: 

• Federal eRulemaking Portal: Go to 

http://www.regulations.gov and follow 

the online instructions for sending your 

comments electronically. 

• Mail: Send comments to Docket 

Operations, M–30; U.S. Department of 

Transportation, 1200 New Jersey 

Avenue, SE., Room W12–140, West 

Building Ground Floor, Washington, DC 

20590–0001. 

• Hand Delivery or Courier: Take 

comments to Docket Operations in 

Room W12–140 of the West Building 

Ground Floor at 1200 New Jersey 

Avenue, SE., Washington, DC, between 

9 a.m. and 5 p.m., Monday through 

Friday, except Federal holidays. 

• Fax: Fax comments to Docket 

Operations at 202–493–2251. 

Privacy: We will post all comments 

we receive, without change, to http:// 

www.regulations.gov, including any 

personal information you provide. 

Using the search function of our docket 

Web site, anyone can find and read the 

electronic form of all comments 

received into any of our dockets, 

including the name of the individual 

sending the comment (or signing the 

comment for an association, business, 

labor union, etc.). You may review 

DOT’s complete Privacy Act Statement 

in the Federal Register published on 

April 11, 2000 (65 FR 19477–78) or you 

may visit http://DocketsInfo.dot.gov. 

Docket: To read background 

documents or comments received, go to 

http://www.regulations.gov at any time 

and follow the online instructions for 

accessing the docket, or, the Docket 

Operations in Room W12–140 of the 

West Building Ground Floor at 1200 

New Jersey Avenue, SE., Washington, 

DC, between 9 a.m. and 5 p.m., Monday 

through Friday, except Federal holidays. 

FOR FURTHER INFORMATION CONTACT: Judi 

Citrenbaum, Federal Air Surgeon’s 

Office, Office of Aerospace Medicine, 

Federal Aviation Administration, 800 

Independence Avenue, SW., 

Washington, DC 20591; telephone (202) 

267–9689; facsimile (202) 267–5200, email Judi.M.Citrenbaum@faa.gov. 

SUPPLEMENTARY INFORMATION: 

Availability of the Policy Statement: 

You can get an electronic copy of this 

document using the Internet by— 

1. Searching the Federal eRulemaking 

Portal (http://www.regulations.gov); 

2. Visiting the FAA’s Regulations and 

Policies Web page at http:// 

www.faa.gov/regulations_policies or 

3. Accessing the Government Printing 

Office’s Web page at http:// 

www.gpoaccess.gov/fr/index.html. 

You can also get a copy by sending a 

request to the Federal Aviation 

Administration, Office of Rulemaking, 

ARM–1, 800 Independence Avenue, 

SW., Washington, DC 20591, or by 

calling (202) 267–9680. Make sure to 

identify the docket number. 

Background 

Under Title 14 of the Code of Federal 

Regulations (14 CFR) 67.107(c), 

67.207(c), and 67.307(c) and 67.113(c), 

67.213(c) and 67.313 (c), the FAA 

generally considers a diagnosis of 

depression and use of psychotropic 

medication medically disqualifying for 

applicants for FAA medical 

certification. Disqualifying medication 

generally includes all sedatives, 

tranquilizers, antipsychotics, 

antidepressants (including selective 

serotonin reuptake inhibitors (SSRIs)), 

analeptics, anxiolytics, and 

hallucinogens. Aviation Medical 

Examiners (AMEs) defer medical 

certificate issuance for any applicant 

with a disqualifying medical condition, 

including any applicant who reveals on 

a medical certificate application usage 

of psychotropic medication for 

treatment of depression. 

Under 14 CFR 67.401 the Federal Air 

Surgeon may, at his discretion, 

authorize special issuance of airman 

medical certificates to applicants who 

are disqualified under the certification 

standards set forth in subparts B, C, or 

D of part 67. The FAA, however, has 

long considered the use of a 

psychotropic medication for treatment 

of depression as a basis to deny a 

special-issuance medical certificate. 

Current FAA special-issuance practice 

has been to consider applicants who 

had taken psychotropic medication only 

if they had discontinued it for at least 

3 months prior to application. Upon 

careful review and reconsideration, the 

FAA is modifying its long-standing, 

special-issuance practice. The FAA has 

determined that aviators diagnosed with 

depression taking one of four specific 


erowe on DSK5CLS3C1PROD with RULES
17048 Federal Register / Vol. 75, No. 64 / Monday, April 5, 2010 / Rules and Regulations 

SSRIs may be considered for special 

issuance of an airman medical 

certificate. Affected applicants will 

continue to be considered on a case-bycase basis and in keeping with the 

conditions and limitations announced 

in this policy statement. 

As reported in the Federal Air 

Surgeon’s Medical Bulletin, Vol. 42, No. 

3, 2004–3 (article entitled ‘‘Depression 

and Use of SSRIs in Pilots’’), since 

developed in the 1980s, SSRIs have 

been used successfully to treat many 

psychiatric disorders and medical 

conditions. Because SSRIs have been 

more effective and better tolerated 

(fewer side effects) than previous 

antidepressant medications, they soon 

became the most frequently prescribed 

medications for depression. Five of the 

top 40 medications prescribed in the 

United States are SSRIs and their usage 

is increasing. 

Some civil aviation authorities have 

adopted more flexible policies to 

consider some applicants using SSRIs. 

Similarly, the International Civil 

Aviation Organization (ICAO), the 

aerospace medical community, and the 

aviation community at large have made 

recommendations that suggest more 

flexibility may be appropriate in some 

cases. These policies and 

recommendations may be summarized 

as follows: 

• Aerospace Medical Association: In 

2004, published a position paper 

recommending that the FAA allow 

usage of SSRIs. 

• Aircraft Owners and Pilots 

Association: In 2006, proposed a change 

to policy and offered a protocol for 

allowing use of certain SSRIs in pilots. 

• Air Line Pilots Association 

Aeromedical Office: In 2002, proposed a 

policy for granting Special-Issuance 

Medical Certificates for selected SSRIs 

and with ongoing medical monitoring. 

• Civil Aviation Safety Authority of 

Australia: In 1987, allowed use of 

certain SSRIs. A 10-year follow-up 

study (1993–2004) of 481 pilots showed 

no increase in accidents. 

• ICAO: In 2009, adopted a 

Recommended Practice that advises that 

signatory States may certificate 

applicants on a case-by-case basis who 

are prescribed (and are taking) an 

approved SSRI antidepressant 

medication for an established diagnosis 

of depression which is in remission. 

• Transport Canada: In 2004, allowed 

(with no adverse affect on safety) six 

pilots holding first-class certificates and 

serving in multi-crew settings selected 

use of only three specific medications. 

• U.S. Army: In 2005, offered a 

waiver for use of SSRIs in selected 

pilots. 

In keeping with these 

recommendations and policies, 

broadening the current special-issuance 

policy on the use of psychotropic 

medication to allow certain 

antidepressants will provide the FAA 

latitude, on a case-by-case basis, to grant 

special-issuance medical certificates to 

applicants determined to be fit for flight. 

For the FAA, concern regarding 

applicants who may be reluctant to 

disclose or who may be masking a 

struggle with depression remains a 

safety concern that this policy will serve 

to address. 

Policies and Recommendations the 

FAA Considered 

In 2004, the Aerospace Medical 

Association (AsMA) [see the docketed 

copy of the article in the journal 

Aviation, Space, and Environmental 

Medicine entitled ‘‘Aeromedical 

Regulation of Aviators Using Selective 

Serotonin Reuptake Inhibitors for 

Depressive Disorders’’ (Vol 75, No. 5)] 

proposed that aeromedical certifying 

authorities remove the current absolute 

prohibition against pilots flying while 

taking SSRIs and adopt aeromedical 

protocols that include carefully 

controlled followup and review. 

According to AsMA: ‘‘Protocols 

designed to aggressively manage the full 

spectrum of adverse possibilities related 

to SSRI use may enable the safe use of 

SSRIs in formerly depressed aviators 

who suffer no aeromedically significant 

side effects. In these closely managed 

cases of depressive disorders, special 

issuances or waivers for SSRI use are 

justified.’’ 

In 2006, the Aircraft Owners and 

Pilots Association requested the FAA to 

reconsider its longstanding policy that 

disallows use of all antidepressant 

medication. In its request, AOPA states 

that the FAA should consider those 

pilots who have a ‘‘demonstrated history 

of continued stability and show no 

adverse symptoms while using 

psychotropic medications, specifically 

SSRIs for a special issuance of a thirdclass medical certificate.’’ 

AOPA indicates that the Civil 

Aviation Safety Authority of Australia 

(CASA) has allowed medical 

certification of aviators using 

antidepressants since 1989. ‘‘Although 

CASA’s policy was not formalized until 

2001, the compiled data of 481 cases did 

yield evidence suggesting that the use of 

antidepressants in carefully screened 

and well-monitored airmen can safely 

be undertaken without compromising 

aviation safety. A smaller study 

conducted by Transport Canada among 

military aviators reached a similar 

conclusion. The results of the 

Australian and Canadian experience 

and the conclusion of aviation medical 

experts clearly favor the use of SSRIs 

under controlled conditions. Because of 

these encouraging results, AOPA 

believes that this is an opportune time 

for the FAA to change its policy 

regarding the use of certain SSRIs.’’ 

An August 2007 research article 

published in the journal Aviation, 

Space, and Environmental Medicine 

(Vol. 78, No. 8) entitled ‘‘Antidepressant 

Use and Safety in Civil Aviation: A 

Case-Control Study of 10 Years of 

Australian Data’’ followed the impact of 

SSRI usage on aviation safety. (A copy 

of this article is placed in the docket.) 

According to the article, the aim of 

the study was ‘‘to identify significant 

safety-related outcomes, such as aircraft 

accidents or incidents that may be 

related to the use of antidepressant 

medication in pilots and air traffic 

controllers.’’ The study employed a 

matched cohort of all holders of 

Australian aviation medical certificates 

who were prescribed antidepressants 

during the period January 1, 1993 to 

June 30, 2004, and a matched 

comparison group. No significant 

differences between the two groups 

were found in any of the analyses. 

Provided specific criteria were met and 

maintained, no evidence of adverse 

safety outcomes was found arising from 

permitting individuals to operate as 

commercial or private aircrew or air 

traffic controllers while using 

antidepressants. 

In November 2009, the International 

Civil Aviation Authority (ICAO) 

adopted a Recommended Practice that 

advises that signatory States may 

certificate applicants on a case-by-case 

basis who are prescribed (and are 

taking) an approved SSRI antidepressant 

medication for an established diagnosis 

of depression which is in remission. 

The recommendation reads as follows: 

6.3.2.2.1, 6.4.2.2.1, 6.5.2.2.1 

Recommendation.—An applicant with 

depression, being treated with antidepressant 

medication, should be assessed as unfit 

unless the medical assessor, having access to 

the details of the case concerned, considers 

the applicant’s condition as unlikely to 

interfere with the safe exercise of the 

applicant’s license and rating privileges. 

In guidelines provided for assessment 

of applicants treated with 

antidepressant medication in its Manual 

of Civil Aviation Medicine (Doc 8984), 

ICAO indicates: ‘‘Some of these 

[antidepressant] medications are 

sedating and some are not, thus offering 

a therapeutic choice in treating 

depressed patients who show 

psychomotor agitation or retardation. 

Fewer side effects generally result in 


erowe on DSK5CLS3C1PROD with RULES
Federal Register / Vol. 75, No. 64 / Monday, April 5, 2010 / Rules and Regulations 17049 

improved aeromedical safety. However, 

successful treatment of depression is a 

dynamic and complex process involving 

more than just writing a prescription, 

and the SSRIs can have some 

aeromedically significant side effects 

and withdrawal effects that are of little 

importance in ordinary clinical practice. 

Aeromedical policies that place an 

absolute prohibition on operating after a 

diagnosis of depression may also make 

it less likely that an aviator or air traffic 

controller will seek treatment or declare 

their illness to the licensing authority.’’ 

Forthcoming Notice Related to This 

Action 

FAA studies have shown that certain 

antidepressants (SSRIs) were found in 

61 pilot fatalities of civil aviation 

accidents that occurred during 1990– 

2001. (See copies of DOT/FAA/AM–07/ 

19 and DOT/FAA/AM–03/7 placed in 

this docket.) In conducting these 

studies, researchers from the FAA Civil 

Aerospace Medical Institute retrieved 

medical information on 59 of the 61 

pilots from the FAA Medical 

Certification Database and accident 

cause/factor information from the 

National Transportation Safety Board’s 

Aviation Accident Database. 

(Information on two pilots was not 

available because one had no medical 

certificate and one held Canadian 

certification). Psychological conditions 

and/or the use of drugs were determined 

to be the cause or a factor in 19 (31%) 

of the 61 accidents. Study findings 

indicated that SSRIs were used by the 

aviators but were not reported in their 

aeromedical examinations. The FAA 

remains concerned that individuals seen 

in the study did not disclose a medical 

history of depression, a related medical 

condition, or SSRI usage. 

According to a May 2004 report 

published in the journal Aviation, 

Space, and Environmental Medicine 

(Vol 75, No. 5) entitled ‘‘Aeromedical 

Regulation of Aviators Using Selective 

Serotonin Reuptake Inhibitors for 

Depressive Disorders,’’ pilots would 

rather risk not taking prescribed 

antidepressant medication than be 

grounded. The report (placed in the 

docket) refers to information about the 

use of SSRIs available from the Aviation 

Medicine Advisory Service (AMAS) of 

Aurora, Colorado which provides 

consultation to various aviation 

organizations such as pilot unions and 

aerospace medicine specialists. This 

database includes information on 

approximately 68,000 pilots working at 

approximately 55 air carriers. According 

to the report: 

AMAS reviewed its database of telephone 

inquiries from pilots between 1992 and 1997. 

It had received 1,200 telephone inquiries 

from pilots who had been diagnosed as 

having clinical depressions, and who had 

been advised by their physicians to take 

antidepressant medications. Under the 

current FAA policy, these pilots would 

spend about 9 mo (sic) off flying status. 

These pilots had called AMAS to discuss the 

aeromedical implications of their situations. 

When advised of the FAA’s policy, that 

each would be grounded until the depression 

had cleared and the medication had been 

discontinued for approximately 3 mo (sic), 

the pilots indicated their intended responses 

to the prospect of not flying for 9 mo (sic) 

or more. Of the 1,200 pilots, some 59% (710) 

told the AMAS that they would refuse the 

medication and continue to fly. About 15% 

(180) indicated an intention to take the 

medications and continue their flight duties 

without informing the FAA. The remaining 

25% (300) said they would take sick leave, 

undergo the recommended treatment, and 

return to work when aeromedically cleared to 

do so. 

Scenarios involving individuals who 

might risk flying while taking an 

antidepressant without medical 

oversight, or flying without taking an 

antidepressant when they need to be, 

are unacceptable. Without condoning 

what we regard as a serious violation of 

FAA regulations and a serious breach of 

the trust on which the aeromedical 

certification system depends, we want 

to encourage pilots who are suffering 

from depression or who are using 

antidepressants to report this 

information honestly. We want 

individuals to be forthcoming about 

depression and antidepressant usage. 

We plan, therefore, to announce in a 

separate Federal Register notice a onetime, limited opportunity to reveal 

previously undisclosed depression and 

use of antidepressant medications 

without being subject to FAA 

enforcement action. Our intent is to 

enhance safety by having those 

individuals suffering from depression 

and using antidepressants do so with 

appropriate aeromedical oversight. 

Policy Statement 

After careful consideration, the FAA 

has determined that selected 

individuals who are being treated for 

depression with one of four specific 

antidepressant medications may be 

considered for special issuance of a 

medical certificate. Individuals granted 

a special-issuance medical certificate 

under this policy may take only one 

type of antidepressant medication 

limited to the following four 

medications: Fluoxetine (Prozac), 

Sertraline (Zoloft), Citalopram (Celexa), 

or Escitalopram (Lexapro). All these 

medications are SSRIs, antidepressants 

that help restore the balance of 

serotonin, a naturally occurring 

chemical substance found in the brain. 

The FAA is limiting consideration of 

special-issuance medical certificates to 

these four medications. Increasingly 

accepted and prevalently used, these 

four antidepressants may be used safely 

in appropriate cases with proper 

oversight and have fewer side effects 

than previous generations of 

antidepressants. While the focus of this 

policy statement is on individuals being 

treated for depression, the FAA realizes 

that these four medications may be used 

to treat conditions other than 

depression. It should be noted, 

therefore, that, in all instances, the FAA 

will continue to consider applicants and 

make determinations on a case-by-case 

basis under the special-issuance process 

just as it always has. 

In addition to treating psychiatrists, 

AMEs who have specialized training 

under a program called the Human 

Intervention and Motivation Study 

(HIMS) also will assist the FAA by 

making recommendations about 

certification cases to be considered 

under this new policy. The HIMS 

program is a safety-critical aviation 

program established nearly 40 years ago. 

The program, developed specifically for 

commercial pilots, was designed as an 

alcohol and drug assistance program to 

coordinate the identification, 

assessment, treatment, and medical 

certification of pilots in need of help. 

Under HIMS, pilots who successfully 

meet rigorous FAA protocols may be 

returned to duty in accordance with 14 

CFR 67.401. The FAA will apply the 

basic HIMS evaluation and monitoring 

approach to this new policy and HIMS 

AMEs will participate in a specialized 

training program tailored to evaluating 

and monitoring applicants who wish to 

be considered under this new policy. 

No regulatory changes are being made 

under this policy. Further, the FAA 

continues to believe that applicants 

requiring use of multiple antidepressant 

medications or use of any other 

psychotropic medication in conjunction 

with any one of the four specified in 

this policy will not meet the criteria set 

forth under this policy. The use of 

psychotropic medication continues to 

be disqualifying under the medical 

standards and special-issuance 

certification will be granted only after 

thorough analysis of each individual 

case presented and only when 

appropriate conditions and limitations 

are in place so that the applicant may 

safely be permitted to operate an 

aircraft. It should be noted that as new 

information becomes available and 

recommendations from the medical 


erowe on DSK5CLS3C1PROD with RULES
17050 Federal Register / Vol. 75, No. 64 / Monday, April 5, 2010 / Rules and Regulations 

community change it may be necessary 

for the FAA to again revise its policy. 

The FAA special-issuance policy will 

include consideration for depression 

treated with certain antidepressant 

medication under the guidance set forth 

as follows: 

CONSIDERATION FOR SPECIAL ISSUANCE OF A MEDICAL CERTIFICATE WITH REGARD TO DEPRESSION TREATED WITH

MEDICATION

This protocol applies to considerations for special-issuance medical certification for airmen requesting first-, second-, and third-class specialissuance medical certificates, for the exercise of privilege under 14 CFR parts 121, 135, or 91, who are being treated with certain 

antidepressant medications. 

Criteria To Be Considered 

Diagnoses 

Mild to moderate depressive disorders, such as: 

Required Reports and Consultations 

(Initial Consideration) 

1. Major Depressive Disorder (mild to moderate) either single episode or recurrent episode 

2. Dysthymic Disorder 

3. Adjustment disorder with depressed mood 

Pharmacologic Agents Considered 

(Single-Agent Use Only) 

1. Fluoxetine (Prozac); 

2. Sertraline (Zoloft); 

3. Citalopram (Celexa); or 

4. Escitalopram (Lexapro) 

Specifically Unacceptable Diagnoses and or Symptoms 

1. Psychosis 

2. Suicidal ideation 

3. History of electro convulsive therapy (ECT) 

4. Treatment with multiple antidepressant medications concurrently 

5. History of multi-agent drug protocol use (prior use of other psychiatric drugs in conjunction with antidepressant medications) 

Psychiatric Status 

1. All symptoms of the psychiatric condition for which treatment is indicated must be ameliorated by the single medication and the condition must be stable with no change in or exacerbation of symptoms 

for 12 months prior to certification; 

2. Airman must be on a stable dosage of medication for a minimum of 

12 months prior to certification; and 

3. Airman must have no aeromedically significant side effects of prescribed medication. 

1. A consultation status report (and follow-up reports as required) from 

a treating psychiatrist attesting to and describing the applicant’s diagnosis, length and course of treatment, dosage of the antidepressant 

medication taken, and presence of any side effects from the 

antidepressant the applicant takes or has taken in the past; 

2. A written statement prepared by the applicant describing his or her 

history of antidepressant usage and mental health status; 

3. A report of the results of neurocognitive psychological tests with provision of the raw test data, including, but not limited to: 

COGSCREEN AE, Trails A/B; Stroop Test; CCPT, PASSAT, Wisconsin Card Sorting Test; 

4. An evaluation and a written report from a HIMS-trained AME who 

has reviewed items 1., 2., and 3. above and who makes a recommendation for a special-issuance medical certificate; and 

5. Any additional information the Federal Air Surgeon may require to 

make a determination. 

Issued in Washington, DC on March 26, 

2010. 

Frederick E. Tilton, 

Federal Air Surgeon. 

[FR Doc. 2010–7527 Filed 4–2–10; 8:45 am] 

BILLING CODE 4910–13–P 

DEPARTMENT OF TRANSPORTATION 

Office of the Secretary 

14 CFR Part 234 

[Docket No. DOT–OST–2010–0039] 

RIN No. 2105–AE00 

Enhancing Airline Passenger 

Protections: Extension of Compliance 

Date for Posting of Flight Delay Data 

on Web Sites 

AGENCY: Office of the Secretary (OST), 

Department of Transportation (DOT). 

ACTION: Final rule; extension of 

compliance date. 

SUMMARY: The Department of 

Transportation is extending by 60 days, 

i.e., until June 29, 2010, the compliance 

date of the provision in its final rule 

entitled ‘‘Enhancing Airline Passenger 

Protections’’ that requires airlines to 

publish flight delay information on their 

Web sites. This extension is in response 

to requests by several carrier 

associations for an additional 90 days 

time for airlines to comply with the 

requirement to display flight delay data 

on Web sites in view of the extensive 

changes to carriers’ reporting systems 

that are necessitated by the rule and 

their contention that completion of 

these tasks is not possible by April 29, 

2010, the current effective date of the 

requirement. The Department agrees 

that additional time to comply with the 

posting of flight delay information on 

the carriers’ Web sites is warranted to 

ensure the posting of complete and 

accurate information but has 

determined that 60 days is enough time 

for the carriers to do so. Therefore, this 

final rule extends the compliance date 

for the provision in question for an 

additional 60 days, from April 29, 2010, 

to June 29, 2010. 

DATES: This amendment further 

amending the final rule published 

December 30, 2009 (74 FR 69002) is 

effective April 29, 2010. 

FOR FURTHER INFORMATION CONTACT: 

Blane A. Workie or Daeleen M. Chesley, 

Office of the Assistant General Counsel 

for Aviation Enforcement and 

Proceedings, U.S. Department of 

Transportation, 1200 New Jersey Ave., 

SE., Washington, DC 20590, 202–366– 

9342 (phone), 202–366–7152 (fax), 

blane.workie@dot.gov or 

daeleen.chesley@dot.gov (e-mail). 

SUPPLEMENTARY INFORMATION: On March 

10, 2010, the Department of 

Transportation published a notice of 


erowe on DSK5CLS3C1PROD with RULES